1887
3 - The International and Scientific Conference of Alnahrain College of Medicine and Colleges of Medicine in Iraq confronting COVID-19 Pandemic (ISMC-2022)
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Severe acute respiratory syndrome coronavirus 2 is the causative agent of coronavirus disease 2019 (COVID-19). The release of alarmins results in a “cytokine storm,” which can be attenuated by the immunomodulatory and anti-inflammatory effects of dexamethasone. To evaluate and assess the effect of dexamethasone in two different doses, on D-dimer, serum ferritin, C-reactive protein (CRP) levels, and granulocyte/lymphocyte (%) in patients with COVID-19. A total of 100 patients were randomly divided into two groups; group A patients received a higher dose of dexamethasone than those in group B. Measurements of certain hematological and biochemical markers, including D-dimer, serum ferritin, CRP, and granulocyte/lymphocyte ratio were done for all the patients in both groups. These indices were compared at different times of treatment between the two groups. The D-dimer and granulocyte/lymphocyte ratio measurements were statistically non-significant in both the groups in all three readings. The serum ferritin measurement was significant only on the 6th day of treatment. The results demonstrated that group A patients had significantly lower CRP levels on both the 3rd and 6th days of treatment. Administration of a slightly higher dose of dexamethasone (8 mg per day for three days, then 6 mg per day for another 3 days) in patients hospitalized with COVID-19 effectively reduces the inflammatory and hematological biomarkers in patients who required supplemental oxygen therapy.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.ismc.4
2022-06-10
2022-06-30
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/3/jemtac.2022.ismc.4.html?itemId=/content/journals/10.5339/jemtac.2022.ismc.4&mimeType=html&fmt=ahah

References

  1. Hammock BD, Wang W, Gilligan MM, Panigrahy D. Eicosanoids: the overlooked storm in COVID-19The American Journal of Pathology. 2020; 190:(9):1782–8.
    [Google Scholar]
  2. Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Internal Medicine. 2020; 180:(9):1152–4.
    [Google Scholar]
  3. Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysisClinical Chemistry and Laboratory Medicine. 2020; 58:(7):1021–8.
    [Google Scholar]
  4. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MV, Baldassare FP. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trialJAMA. 2020; 324:(13):1307–16.
    [Google Scholar]
  5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a reviewJAMA. 2020; 324:(8):782–93.
    [Google Scholar]
  6. Dirican A, Uzar T, Karaman I, Uluisik A, Ozakaya S. Trying to Find the Answer for Two Questions in Patients with COVID-19: 1.Is pulmonary infiltrate of COVID-19 infective or inflammatory in nature (Pneumonia or Pneumonitis)? 2.Is Hydroxychloroquine plus Azithromycin or Favipiravir plus Dexamethasone more effective in the COVID-19 treatment? medRxiv. 2020. doi: 10.1101/2020.08.25.20181388 .
    [Google Scholar]
  7. Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LC, Berwanger O, Cavalcanti AB, Dequin PF. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysisJAMA. 2020; 324:(13):1330–41.
    [Google Scholar]
  8. Águas R, Mahdi A, Shretta R, Horby P, Landray M, White LJ. The potential health and economic impact of dexamethasone treatment for patients with COVID-19medRxiv. 2020. doi: 10.1101/2020.07.29.20164269 .
    [Google Scholar]
  9. Doyle DJ, Goyal A, Garmon EH. American Society of Anesthesiologists Classification. [Updated 2022 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441940/.
    [Google Scholar]
  10. ASA Physical Status Classification System [Internet]. Asahq.org. 2022 [cited 1 April 2022]. Available from: https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system .
    [Google Scholar]
  11. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19Drugs. 2020; 80:(13):1267–92.
    [Google Scholar]
  12. Raymond M Jonson, et al. Dexamethasone in the management of COVID-19.2020;370. doi: https://doi.org/10.1136/bmj.m2648 (Published 03 July 2020).
    [Google Scholar]
  13. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25; 384:(8):693-704. doi: 10.1056/NEJMoa2021436 .
    [Google Scholar]
  14. Jan Maláska,Ja Maláska, J., Stašek, J., Duška, F, et al. Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)—study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial. Trials 2022; 23:(1):35. https://doi.org/10.1186/s13063-021-05963-6.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.ismc.4
Loading
/content/journals/10.5339/jemtac.2022.ismc.4
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): COVID-19dexamethasone and SARS COV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error